Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

ASX:SUN
ASX:SUNInsurance

Does Suncorp’s Hybrid Note Issue Signal a Strategic Shift in Its Capital Mix (ASX:SUN)?

Suncorp Group Limited recently completed a Fixed-Income Offering, issuing A$200 million of Floating Rate Hybrid Notes that are convertible, non-cumulative and subordinated, with a variable coupon structure. This hybrid issuance adds a new layer to Suncorp’s capital structure, blending debt and equity characteristics that may influence how investors assess its funding mix and risk profile. We’ll now examine how Suncorp’s use of subordinated, floating rate hybrid capital could reshape its...
NasdaqGS:ALGN
NasdaqGS:ALGNMedical Equipment

Align Technology (ALGN) Margin Resilience Reinforces Bullish Narratives After Q1 2026 Earnings

Align Technology (ALGN) opened 2026 with Q1 revenue of about US$1.0 billion and basic EPS of US$1.58, setting the tone for how investors will read the rest of the year. The company has seen quarterly revenue move from US$979.3 million in Q1 2025 through US$995.2 million in Q4 2024 to just over US$1.0 billion in the latest quarter, while basic EPS over the same span ranged from US$1.27 in Q1 2025 to US$1.89 in Q4 2025 before landing at US$1.58 in Q1 2026. This provides a clear run-rate on both...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

O'Reilly Automotive (ORLY) Earnings Growth Outpaces Five Year Trend Reinforcing Bullish Margin Narrative

O'Reilly Automotive (ORLY) opened 2026 with Q1 revenue of US$4.6b and basic EPS of US$0.72, supported by trailing twelve month revenue of US$18.2b and EPS of US$3.08 that point to earnings growth of 9.5% over the past year. Over the last five reported quarters, the company has seen revenue move from US$4.1b in Q1 2025 to US$4.6b in Q1 2026, while quarterly EPS ranged between US$0.63 and US$0.86 across that period as trailing net income reached US$2.6b. With net profit margins running at...
NasdaqGS:STNE
NasdaqGS:STNEDiversified Financial

Is StoneCo (STNE) Now An Opportunity After Recent Share Price Slide?

This article examines whether StoneCo, trading at around US$10.98, could be considered a bargain or a value trap by focusing on what the current share price might imply about the company. The stock has experienced significant recent volatility, with a 24.5% decline over the last week, a 22.2% decline over the last month, and a 25.3% decline year to date. Over longer periods, the 1 year return shows a 4.3% decline and the 5 year return a 78.3% decline. Recent commentary around StoneCo has...
ENXTBR:ABI
ENXTBR:ABIBeverage

Dividend Hike and Board Refresh Could Be A Game Changer For Anheuser-Busch InBev (ENXTBR:ABI)

At its 29 April 2026 shareholder meeting, Anheuser-Busch InBev approved a €1.15 gross total dividend for 2025 and refreshed its board, appointing Fabrizio Freda and Miguel Patricio as directors alongside new Restricted Share Directors. Coupled with a planned US$600.00 million investment in U.S. manufacturing and workforce training, these moves highlight AB InBev’s focus on strengthening operations and supporting shareholder returns. Next, we’ll examine how AB InBev’s newly approved...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics ADA Data Could Reframe Oral Obesity And Diabetes Prospects

Structure Therapeutics (NasdaqGM:GPCR) plans multiple presentations at the 86th American Diabetes Association Scientific Sessions. The company will share new safety, efficacy, and dosing data for its oral GLP-1 receptor agonist aleniglipron. Additional data will cover a novel amylin receptor agonist combination, including findings on weight loss effects. The presentations focus on combination approaches in obesity and diabetes treatment development. Structure Therapeutics focuses on oral...
SEHK:1810
SEHK:1810Tech

Is It Time To Reconsider Xiaomi (SEHK:1810) After Its Recent Share Price Slide

If you are wondering whether Xiaomi's current share price reflects its true worth, the recent mix of sharp swings and long term gains gives you plenty to think about. The stock is around HK$29.02, with a 7% decline over the last week, a 9.4% decline over the last month, a 28% decline year to date, a 45.3% decline over the last year, and a 160% gain over the last three years. Recent news around Xiaomi has focused on its position in consumer electronics and smartphones, as well as its efforts...
NasdaqGM:CAMT
NasdaqGM:CAMTSemiconductor

Is It Too Late To Consider Camtek (CAMT) After Its 191% One Year Surge

If you are wondering whether Camtek's current share price reflects its underlying value, you are not alone. That question is exactly what this article will help you think through. Camtek's stock has been volatile recently, with a 2% decline over the last week, a 26.6% gain over the last 30 days, a 66.2% return year to date, and a 191.3% return over the last year, along with very large multi year gains. These moves have put Camtek firmly on many investors' radars, and recent coverage has...
TSX:SOBO
TSX:SOBOOil and Gas

Does South Bow (TSX:SOBO) Price Reflect Its Cash Flow And Earnings Valuation Signals?

If you are wondering whether South Bow's current share price reflects its real worth, this article walks through the key signals that matter for value focused investors. Over the recent period, South Bow's share price closed at C$46.50, with returns of 6.5% over 7 days, 0.5% over 30 days, 21.5% year to date, and 44.5% over 1 year that many investors will be weighing against the underlying fundamentals. Recent coverage has highlighted South Bow's share price performance and how investors are...
XTRA:MRK
XTRA:MRKPharmaceuticals

Merck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables

Merck KGaA (XTRA:MRK) announced a collaboration with Remepy to develop Hybrid Drugs that pair pharmaceuticals with app-based digital therapeutics for rare and difficult-to-treat cancers. The company also introduced its first bio-based solvent portfolio for high-performance liquid chromatography, aimed at supporting more sustainable laboratory operations. For you as an investor, these moves highlight how Merck KGaA is leaning into two active themes in healthcare: digital therapeutics and...
NYSE:CLX
NYSE:CLXHousehold Products

Clorox’s Purell Deal Expands Health Focus As Earnings Outlook Softens

Clorox, NYSE:CLX, has completed its acquisition of GOJO Industries, the owner of the Purell brand. The deal adds a broad health and hygiene portfolio to Clorox's existing cleaning and household products. This transaction reflects a move to broaden Clorox's exposure beyond traditional household categories. Clorox enters this deal with its shares at $96.44, after a 27.3% decline over the past year and a 38.1% decline over the past five years. The acquisition of GOJO and Purell gives the...
ENXTPA:RI
ENXTPA:RIBeverage

Is Pernod Ricard (ENXTPA:RI) Starting To Look Interesting After Its Sharp Share Price Slide?

Wondering whether Pernod Ricard is starting to look attractive at today’s price, or if the market still sees more downside? The stock last closed at €62.84, with returns of a 4.5% decline over 7 days, 2.1% decline over 30 days, 13.9% decline year to date, 30.3% decline over 1 year, 67.0% decline over 3 years and 57.7% decline over 5 years. This naturally raises questions about how its current price stacks up against its fundamentals. Recent coverage has focused on how sentiment toward...
NYSE:LHX
NYSE:LHXAerospace & Defense

L3Harris Technologies (LHX) Heads Into Q1 2026 With 7.3% Net Margin Reinforcing Bullish Narratives

L3Harris Technologies (LHX) has kicked off its Q1 2026 reporting cycle with investors looking back at a steady run of quarterly numbers, where 2025 revenue ranged from US$5,132 million to US$5,659 million and basic EPS moved between US$1.60 and US$2.47. Over the last year, the company has seen total revenue hold around US$21.2 billion on a trailing basis, while trailing EPS has tracked between US$7.91 and US$9.35. This provides a clear sense of consistent top line scale and earnings power as...
ASX:COH
ASX:COHMedical Equipment

How Cochlear’s FY26 Profit Downgrade At Cochlear (ASX:COH) Has Changed Its Investment Story

Cochlear Limited recently downgraded its FY26 net profit guidance from A$435–A$460 million to A$290–A$330 million, citing softer demand, delayed surgeries, and geopolitical disruptions in key markets. This setback has drawn attention to how dependent Cochlear’s earnings are on procedure volumes and hospital capacity, despite its strong competitive position in implantable hearing solutions. We’ll now examine how this earnings guidance cut, driven by weaker demand and delayed surgeries, may...
BIT:RACE
BIT:RACEAuto

Is Ferrari (BIT:RACE) Pricing Still Justified After A 26% One-Year Share Price Slide

If you are wondering whether Ferrari's current share price reflects its true worth, you are not alone. This article focuses on what the numbers suggest about value rather than the brand's prestige. Ferrari shares last closed at €293.35, after a 4.1% decline over the past week, a 1.5% gain over the last month, and returns of 7.3% decline year to date and 26.1% decline over the past year. This may catch the eye of investors reassessing risk and opportunity. Recent coverage has highlighted...
OM:ERIC B
OM:ERIC BCommunications

Is It Time To Reassess Ericsson (OM:ERIC B) After Its Strong Three Year Share Price Run

Wondering if Telefonaktiebolaget LM Ericsson is fairly priced or if the market is overlooking something? This article walks through the key numbers so you can judge the current share price with more confidence. The stock last closed at SEK108.35 and has returns of 2.6% over 7 days, 1.9% over 30 days, 22.7% year to date and 37.6% over 1 year, with a 121.0% return over 3 years and 12.8% over 5 years. Recent share price performance sits alongside an ongoing flow of news around Ericsson's role...
NasdaqGS:WBD
NasdaqGS:WBDEntertainment

Is It Too Late To Consider Warner Bros. Discovery (WBD) After 221% One Year Surge?

If you are wondering whether Warner Bros. Discovery at around US$27.05 is still offering value after a strong run, this breakdown will help you understand what the current price actually reflects. The stock has returned 0.6% over the last week and 220.9% over the past year, even though the year to date return sits at a 5.1% decline and the five year return is a 25.4% decline. Recent headlines have focused on Warner Bros. Discovery's positioning across streaming, film, and TV content, as...
NYSE:LMND
NYSE:LMNDInsurance

Lemonade (LMND) Losses Narrow In Q4 2025 Challenging Bearish Profitability Narratives

Lemonade (LMND) opened Q1 2026 earnings season with Q4 2025 revenue of US$228.4 million and a basic EPS loss of US$0.29, alongside net income excluding extra items of a US$21.7 million loss. Over the past year, the company reported quarterly revenue increasing from US$151.2 million in Q1 2025 to US$228.4 million in Q4 2025, while quarterly basic EPS losses narrowed from US$0.86 in Q1 2025 to US$0.29 in Q4 2025. For investors, the latest results focus attention on how quickly Lemonade can...
ENXTPA:MC
ENXTPA:MCLuxury

Why LVMH (ENXTPA:MC) Is Down 5.0% After Dividend Approval And Revenue Decline Amid Middle East Tensions

In April 2026, LVMH Moët Hennessy - Louis Vuitton’s shareholders approved a €13.00 per-share dividend for 2025, while the group also reported a 6% revenue decline linked partly to Middle East disruption and temporary store closures. At the same time, LVMH and its Stella McCartney brand face a U.S. lawsuit alleging anti-competitive pricing, pay disparities, and whistleblower retaliation, adding legal and governance questions to existing geopolitical and demand pressures on the luxury...
NYSE:JOE
NYSE:JOEReal Estate

St. Joe (JOE) Q1 EPS Compression Tests Bullish Premium Multiple Narrative

St. Joe (JOE) opened 2026 with Q1 revenue of US$99 million and basic EPS of US$0.24, compared with Q1 2025 revenue of US$94 million and EPS of US$0.30. Trailing twelve month EPS stood at US$1.94 on revenue of US$518 million. Over that same twelve month stretch, net income reached US$112 million, giving investors a fuller view of how quarterly earnings feed into the broader profit picture. With a net margin of 21.6% over the last year, the latest numbers keep the spotlight firmly on how...